Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 8Observational 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion 1Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion 1

Interventions

Surveys and Questionnaires 53Blood Specimen Collection 53Specimen Handling 28Radiotherapy 18Observation 18Interviews as Topic 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Drug Therapy 10Data Collection 10Biopsy 10Tomography, X-Ray Computed 9darolutamide 8Watchful Waiting 7Standard of Care 7ribociclib 6palbociclib 6Restraint, Physical 6Patient Reported Outcome Measures 6Magnetic Resonance Imaging 6Immune Checkpoint Inhibitors 6trastuzumab deruxtecan 5Positron-Emission Tomography 5Mass Screening 5Genetic Testing 5Esophagectomy 5Breath Tests 5Bevacizumab 5enzalutamide 4apalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × larotrectinib × 90 days × Clear all
NCT04142437 2026-04-14

ON-TRK

Bayer

Recruiting
150 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

NCT04945330 2026-04-14

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Bayer

Recruiting
100 enrolled
Other solid neoplasm

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡